08.08.17
MilliporeSigma has formed a strategic alliance with Baylor College of Medicine, Houston, TX, and its partner, Texas Children's Hospital Center for Vaccine Development, to advance vaccine research and development for neglected and emerging infections.
The collaboration focuses on bringing vaccines through development more efficiently. MilliporeSigma's process development and formulation teams are working with Texas Children's CVD scientists at Baylor to optimize the vaccine manufacturing process to increase vaccine stability and yield. Initially, these activities are targeting schistosomiasis, a deadly parasitic disease that affects millions of people a year in tropical and subtropical regions.
"Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community," said Udit Batra, chief executive officer, MilliporeSigma. "The alliance with Baylor College of Medicine, one of the premier research universities in the world, is the ideal partnership to advance vaccine development and manufacturing. Together, we will support the fight against infectious diseases."
The collaboration includes training and exchange of technical know-how in process development and formulation, filling knowledge gaps that exist from research and development to manufacturing, with a focus on neglected and emerging diseases.
The collaboration focuses on bringing vaccines through development more efficiently. MilliporeSigma's process development and formulation teams are working with Texas Children's CVD scientists at Baylor to optimize the vaccine manufacturing process to increase vaccine stability and yield. Initially, these activities are targeting schistosomiasis, a deadly parasitic disease that affects millions of people a year in tropical and subtropical regions.
"Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community," said Udit Batra, chief executive officer, MilliporeSigma. "The alliance with Baylor College of Medicine, one of the premier research universities in the world, is the ideal partnership to advance vaccine development and manufacturing. Together, we will support the fight against infectious diseases."
The collaboration includes training and exchange of technical know-how in process development and formulation, filling knowledge gaps that exist from research and development to manufacturing, with a focus on neglected and emerging diseases.